Thursday Mar 28, 2024
Thursday Mar 28, 2024

European agency studying new COVID-19 treatment

EU drug regulator start rolling review of Sotrovimab


Nepalnews
2021 May 07, 16:39, London
European Medicines Agency logo Photo: Wikimedia

The European Medicines Agency says it has begun an accelerated authorization process for an experimental coronavirus treatment made by GlaxoSmithKline and Vir BioTechnology.

In a statement on Friday, the EU drug regulator said it had started a rolling review of Sotrovimab, based on early results from an ongoing study into whether the treatment can prevent hospitalization or death in people who don’t yet have severe COVID-19. But EMA said it had not yet received the complete data and cautioned that “it is too early to draw any conclusions about the benefit-risk balance of the medication.”

Although the EMA has given the green light to four vaccines, there are few licensed treatments for the coronavirus, especially any that might prevent people with mild COVID-19 from progressing to severe disease.

Sotrovimab is a monoclonal antibody, a lab-produced antibody that is intended to stimulate the immune system by reducing the ability of the coronavirus’s spike protein to enter the body’s cells.

An emergency use authorization for Sotrovimab has also been submitted to regulators in the US and Canada.

READ ALSO:

European Medicines Agency EMA covid-19 coronavirus treatment GlaxoSmithKline Vir BioTechnology Sotrovimab
Nepal's First Online News Portal
Published by Nepalnews Pvt Ltd
Editor: Raju Silwal
Information Department Registration No. 1505 / 076-77

Contact

KMC-02, UttarDhoka,
Lazimpat, Nepal

Newsroom
+977–01–4445751 / 4445754

E-mail
[email protected] [email protected]

Terms of Use Disclaimer
© NepalNews. 2021 All rights reserved. | Nepal's First News Portal